Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Other Non-Current Assets (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Other Non-Current Assets for 16 consecutive years, with $3.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets rose 64.91% to $3.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.8 million, a 64.91% increase, with the full-year FY2024 number at $2.8 million, down 56.23% from a year prior.
  • Other Non-Current Assets was $3.8 million for Q3 2025 at Harvard Bioscience, roughly flat from $3.8 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $8.7 million in Q2 2022 to a low of $724000.0 in Q3 2021.
  • A 5-year average of $4.8 million and a median of $4.8 million in 2024 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: surged 1047.24% in 2022, then crashed 69.39% in 2024.
  • Harvard Bioscience's Other Non-Current Assets stood at $5.4 million in 2021, then skyrocketed by 44.74% to $7.8 million in 2022, then dropped by 16.8% to $6.5 million in 2023, then tumbled by 56.23% to $2.8 million in 2024, then surged by 33.89% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Other Non-Current Assets are $3.8 million (Q3 2025), $3.8 million (Q2 2025), and $3.5 million (Q1 2025).